Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07552077 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
A Phase 2 study, sponsored by Palvella Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07552077 is a Phase 2 study that is actively recruiting participants, run by Palvella Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT07552077, a Phase 2 study, is actively recruiting participants, sponsored by Palvella Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Interventions
- DRUG PTX-022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07552077
The ClinicalTrials.gov registry entry for NCT07552077 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palvella Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTX-022 is the first listed.
NCT07552077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07552077 about?
NCT07552077 is a clinical study titled "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)". The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
What is the current status of trial NCT07552077?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07552077?
The interventions under investigation include: PTX-022 (DRUG).
Who is sponsoring clinical trial NCT07552077?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.